Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

June 4, 2017

Primary Completion Date

February 20, 2018

Study Completion Date

February 20, 2018

Conditions
Malaria Vaccine
Interventions
BIOLOGICAL

RTS,S/AS01B Fractional dose

RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.

BIOLOGICAL

Double RTS,S/AS01E Fractional dose

A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.

BIOLOGICAL

RTS,S/AS01E Standard dose

RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.

BIOLOGICAL

RTS,S/AS01E + DHA-PIP+PQ Standard dose

RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2

BIOLOGICAL

RTS,S/AS01E Fractional dose

RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.

BIOLOGICAL

RTS,S/AS01E + DHA-PIP+PQ Fractional dose

RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.

BIOLOGICAL

RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose

RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2

Trial Locations (1)

10400

Hospital of Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02992119 - Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults | Biotech Hunter | Biotech Hunter